EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Predictive Factors of Early 18 F-Fluorodeoxyglucose-Positron Emission Tomography Response to [ 131 I] Metaiodobenzylguanidine Treatment for Unresectable or Metastatic Pheochromocytomas and Paragangliomas

Junki Takenaka, Shiro Watanabe, Takashige Abe, Takahiro Tsuchikawa, Satoshi Takeuchi, Kenji Hirata, Rina Kimura, Naoto Wakabayashi, Nobuo Shinohara, Kohsuke Kudo

Neuroendocrinology · 2023

DOI: 10.1159/000534175 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuroendocrinology, 2023. Verfasst von Junki Takenaka und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Diagnostic Imaging, Graduate School of Medicine, Hokkaido University, Sapporo, Japan, jtakenaka@pop.med.hokudai.ac.jp. Hauptthemen laut MEDLINE: Pheochromocytoma, 3-Iodobenzylguanidine, Paraganglioma, Fluorodeoxyglucose F18. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Pheochromocytomas and paragangliomas (PPGLs) are rare neuroendocrine tumours that produce catecholamines. [131I] metaiodobenzylguanidine (MIBG)-avid unresectable or metastatic PPGLs are treated with [131I] MIBG radionuclide therapy. A high metabolic tumour volume (MTV) and total lesion glycolysis (TLG) can be poor prognostic factors. Therefore, we evaluated the metabolic responses to [131I] MIBG therapy with respect to other clinical factors.

Methods

A retrospective study was performed on a series of 20 patients who underwent FDG-PET before and after [131I] MIBG therapy. We administered a single dose comprising 5.5 GBq of [131I] MIBG (usually three times; for some cases, the number was increased or decreased considering treatment efficacy and side effects). Semi-quantitative parameters (SUVmax, MTV, and TLG) were calculated using the liver SUV (mean + 3 × standard deviation) as a threshold on Metavol software. The semi-quantitative FDG-PET parameters for determining response were complete response (CR), partial remission (PR), stable disease (SD), and progressive disease (PD). We divided our study participants into the PD and non-PD groups (i.e., SD + PR + CR) and compared the overall survival (OS) between the two groups. Subsequently, we evaluated the relationships between metabolic response and age, sex, tumour type, metastatic site, chemotherapy or external radiation history, and 24-h urine catecholamine levels by univariate logistic regression analyses.

Results

Both MTV-based and TLG-based criteria for PD versus non-PD were significant prognostic factors (p = 0.014). However, treatment response as evaluated based on the SUVmax was not a significant predictor. Higher urinary dopamine levels were associated with poor metabolic response as assessed by MTV and TLG (OR 1.002, p = 0.029). The other clinical parameters were non-significant.

Conclusion

Poor metabolic response (measured with MTV and TLG) to [131I] MIBG therapy in unresectable or metastatic PPGLs was related to shorter OS. The poor metabolic response can be predicted using the urinary dopamine level.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pheochromocytoma3-IodobenzylguanidineParagangliomaFluorodeoxyglucose F18Adrenal Gland NeoplasmsPositron-Emission TomographyHumansFemaleMaleMiddle AgedRetrospective StudiesAdultAgedRadiopharmaceuticalsTreatment OutcomePrognosisYoung Adult

Stichwörter der Autor:innen

18F-fluorodeoxyglucose-positron emission tomographyPheochromocytoma and paragangliomaUrine catecholamine[131I] metaiodobenzylguanidine therapy

Substanzen

3-IodobenzylguanidineFluorodeoxyglucose F18Radiopharmaceuticals

Autor:innen und Institutionen

  • Department of Diagnostic Imaging, Graduate School of Medicine, Hokkaido University, Sapporo, Japan, jtakenaka@pop.med.hokudai.ac.jp.
  • Department of Nuclear Medicine, Hokkaido University Hospital, Sapporo, Japan, jtakenaka@pop.med.hokudai.ac.jp.
  • Department of Diagnostic Imaging, Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
  • Department of Nuclear Medicine, Hokkaido University Hospital, Sapporo, Japan.
  • Global Center for Biomedical Science and Engineering, Faculty of Medicine, Hokkaido University, Sapporo, Japan.
  • Department of Renal and Genitourinary Surgery, Hokkaido University Graduate School of Medicine, Sapporo, Japan.

Zitieren

APA

Takenaka, J., Watanabe, S., Abe, T., Tsuchikawa, T., Takeuchi, S., Hirata, K., Kimura, R., Wakabayashi, N., Shinohara, N., & Kudo, K. (2023). Predictive Factors of Early 18 F-Fluorodeoxyglucose-Positron Emission Tomography Response to [ 131 I] Metaiodobenzylguanidine Treatment for Unresectable or Metastatic Pheochromocytomas and Paragangliomas. Neuroendocrinology. https://doi.org/10.1159/000534175

Vancouver

Takenaka J, Watanabe S, Abe T, Tsuchikawa T, Takeuchi S, Hirata K, et al. Predictive Factors of Early 18 F-Fluorodeoxyglucose-Positron Emission Tomography Response to [ 131 I] Metaiodobenzylguanidine Treatment for Unresectable or Metastatic Pheochromocytomas and Paragangliomas. Neuroendocrinology. 2023. doi:10.1159/000534175

BibTeX
@article{Takenaka2023,
  author = {Takenaka, Junki and Watanabe, Shiro and Abe, Takashige and Tsuchikawa, Takahiro and Takeuchi, Satoshi and Hirata, Kenji and Kimura, Rina and Wakabayashi, Naoto and Shinohara, Nobuo and Kudo, Kohsuke},
  title = {Predictive Factors of Early 18 F-Fluorodeoxyglucose-Positron Emission Tomography Response to [ 131 I] Metaiodobenzylguanidine Treatment for Unresectable or Metastatic Pheochromocytomas and Paragangliomas},
  journal = {Neuroendocrinology},
  year = {2023},
  doi = {10.1159/000534175}
}
Kostenlos starten →